Title

Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors

Publication Date

2020

Presented At:

2020 ASCO Annual Meeting

Content Type

Conference - Abstract

Publisher's Site:

View at Publisher Website

Additional Authors:

Additional authors and institutional affiliations

This document is currently not available here.

Share

COinS